A Chinese phase 3 trial of Bristol…
A Chinese phase 3 trial of Bristol Myers Squibb’s antibody-drug [...]
While the FDA mulls whether to…
While the FDA mulls whether to approve Protagonist Therapeutics’ hematology [...]
After promising to sell off 7% of…
After promising to sell off 7% of its business back [...]
In developing media plans to reach…
In developing media plans to reach the GLP-1-interested consumer, audio [...]
When BridgeBio presented its…
When BridgeBio presented its quarterly report on Tuesday, it laid [...]
The federal government is pledging…
The federal government is pledging as much as $144 million [...]
After dumping its sole remaining…
After dumping its sole remaining gene therapy asset last year, [...]
Like Merck & Co.’s PAH drug…
Like Merck & Co.’s PAH drug Winrevair—which brought in $1.4 [...]
Harbour BioMed is setting sail as…
Harbour BioMed is setting sail as the Solstice begins, riding [...]
Amid efforts on several fronts to…
Amid efforts on several fronts to improve the affordability of [...]